首頁 > 市場調查報告書 > 製藥

自體免疫疾病

全球僵直性脊椎炎市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測

市場調查報告書

商品編碼

1377873

全球僵直性脊椎炎市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測

Global Ankylosing Spondylitis Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年09月01日 | 出版商:

Value Market Research | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計全球僵直性脊椎炎市場需求將從 2022 年的 52.9 億美元增至 2030 年的近 108.5 億美元，2023-2030 年研究期間CAGR為 9.4%。

僵直性脊椎炎 (AS) 是一種持續性自體免疫疾病，主要針對脊椎和薦髂關節，但也會影響其他關節和器官。它屬於脊椎關節炎類別，是一組以關節和附著點發炎（韌帶和肌腱附著在骨骼上的位置）為特徵的疾病。

市場動態：

對僵直性脊椎炎認知的提高、診斷方法的改進以及治療方案的進步，特別是生物療法和疾病緩解藥物，正在推動市場發展。全球人口老化導致更多人面臨這種疾病的風險，進一步增加了對僵直性脊椎炎相關醫療保健服務的需求。基因研究和新興市場正在擴大市場範圍。監管支持、以患者為中心的護理和數位健康解決方案也正在推動僵直性脊椎炎市場向前發展。正在進行的研究和臨床試驗有望帶來新的治療方式和療法，促進其管理的持續創新。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球僵直性脊椎炎市場的每個細分市場進行了包容性評估。僵直性脊椎炎產業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲僵直性脊椎炎市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。僵直性脊椎炎市場的主要參與者包括艾伯維公司、安進公司、輝瑞公司、諾華公司、禮來公司、UCB公司。本節包括競爭格局的整體視圖，其中包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 7 章：僵直性脊椎炎公司的競爭格局

僵直性脊椎炎市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 8 章：公司簡介

公司股份分析
市場集中度
AbbVie, Inc.

公司簡介
公司收入
產品
最近的發展

Amgen, Inc.

公司簡介
公司收入
產品
最近的發展

Pfizer, Inc.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Eli Lilly and Company

公司簡介
公司收入
產品
最近的發展

UCB, Inc.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112112244

The global demand for Ankylosing Spondylitis Market is presumed to reach the market size of nearly USD 10.85 BN by 2030 from USD 5.29 BN in 2022 with a CAGR of 9.4% under the study period 2023 - 2030.

Ankylosing spondylitis (AS) is a persistent autoimmune condition that predominantly targets the spine and sacroiliac joints, but it can also impact other joints and organs. It belongs to the category of spondyloarthritis, a cluster of disorders characterized by joint and enthesis inflammation (the locations where ligaments and tendons attach to bones).

MARKET DYNAMICS:

Increased awareness of ankylosing spondylitis, improved diagnostic methods, and advancements in treatment options, particularly biologic therapies and disease-modifying drugs, are driving the market. The aging global population contributes to a greater number of individuals at risk of this condition, further increasing demand for ankylosing spondylitis-related healthcare services. Genetic research and emerging markets are expanding the market's reach. Regulatory support, patient-centric care, and digital health solutions are also propelling the ankylosing spondylitis market forward. Ongoing research and clinical trials promise new treatment modalities and therapies, fostering continued innovation in its management.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of ankylosing spondylitis. The growth and trends of ankylosing spondylitis industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the ankylosing spondylitis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug

Cosentyx
Humira
Simponi
Remicade
Enbrel
Cimzia
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Ankylosing Spondylitis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Ankylosing Spondylitis market include AbbVie, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Eli Lilly and Company, UCB, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ANKYLOSING SPONDYLITIS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug
- 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANKYLOSING SPONDYLITIS MARKET ANALYSIS BY DRUG

5.1 Overview by Drug
5.2 Historical and Forecast Data
5.3 Analysis by Drug
5.4 Cosentyx Historic and Forecast Sales by Regions
5.5 Humira Historic and Forecast Sales by Regions
5.6 Simponi Historic and Forecast Sales by Regions
5.7 Remicade Historic and Forecast Sales by Regions
5.8 Enbrel Historic and Forecast Sales by Regions
5.9 Cimzia Historic and Forecast Sales by Regions
5.10. Others Historic and Forecast Sales by Regions

6 . GLOBAL ANKYLOSING SPONDYLITIS MARKET ANALYSIS BY GEOGRAPHY

6.1. Regional Outlook
6.2. Introduction
6.3. North America Sales Analysis
- 6.3.1. Overview, Historic and Forecast Data Sales Analysis
- 6.3.2. North America By Segment Sales Analysis
- 6.3.3. North America By Country Sales Analysis
- 6.3.4. United State Sales Analysis
- 6.3.5. Canada Sales Analysis
- 6.3.6. Mexico Sales Analysis
6.4. Europe Sales Analysis
- 6.4.1. Overview, Historic and Forecast Data Sales Analysis
- 6.4.2. Europe by Segment Sales Analysis
- 6.4.3. Europe by Country Sales Analysis
- 6.4.4. United Kingdom Sales Analysis
- 6.4.5. France Sales Analysis
- 6.4.6. Germany Sales Analysis
- 6.4.7. Italy Sales Analysis
- 6.4.8. Russia Sales Analysis
- 6.4.9. Rest Of Europe Sales Analysis
6.5. Asia Pacific Sales Analysis
- 6.5.1. Overview, Historic and Forecast Data Sales Analysis
- 6.5.2. Asia Pacific by Segment Sales Analysis
- 6.5.3. Asia Pacific by Country Sales Analysis
- 6.5.4. China Sales Analysis
- 6.5.5. India Sales Analysis
- 6.5.6. Japan Sales Analysis
- 6.5.7. South Korea Sales Analysis
- 6.5.8. Australia Sales Analysis
- 6.5.9. South East Asia Sales Analysis
- 6.5.10. Rest Of Asia Pacific Sales Analysis
6.6. Latin America Sales Analysis
- 6.6.1. Overview, Historic and Forecast Data Sales Analysis
- 6.6.2. Latin America by Segment Sales Analysis
- 6.6.3. Latin America by Country Sales Analysis
- 6.6.4. Brazil Sales Analysis
- 6.6.5. Argentina Sales Analysis
- 6.6.6. Peru Sales Analysis
- 6.6.7. Chile Sales Analysis
- 6.6.8. Rest of Latin America Sales Analysis
6.7. Middle East & Africa Sales Analysis
- 6.7.1. Overview, Historic and Forecast Data Sales Analysis
- 6.7.2. Middle East & Africa by Segment Sales Analysis
- 6.7.3. Middle East & Africa by Country Sales Analysis
- 6.7.4. Saudi Arabia Sales Analysis
- 6.7.5. UAE Sales Analysis
- 6.7.6. Israel Sales Analysis
- 6.7.7. South Africa Sales Analysis
- 6.7.8. Rest Of Middle East And Africa Sales Analysis

7 . COMPETITIVE LANDSCAPE OF THE ANKYLOSING SPONDYLITIS COMPANIES

7.1. Ankylosing Spondylitis Market Competition
7.2. Partnership/Collaboration/Agreement
7.3. Merger And Acquisitions
7.4. New Product Launch
7.5. Other Developments

8 . COMPANY PROFILES OF ANKYLOSING SPONDYLITIS INDUSTRY

8.1. Company Share Analysis
8.2. Market Concentration Rate
8.3. AbbVie, Inc.
- 8.3.1. Company Overview
- 8.3.2. Company Revenue
- 8.3.3. Products
- 8.3.4. Recent Developments
8.4. Amgen, Inc.
- 8.4.1. Company Overview
- 8.4.2. Company Revenue
- 8.4.3. Products
- 8.4.4. Recent Developments
8.5. Pfizer, Inc.
- 8.5.1. Company Overview
- 8.5.2. Company Revenue
- 8.5.3. Products
- 8.5.4. Recent Developments
8.6. Novartis AG
- 8.6.1. Company Overview
- 8.6.2. Company Revenue
- 8.6.3. Products
- 8.6.4. Recent Developments
8.7. Eli Lilly and Company
- 8.7.1. Company Overview
- 8.7.2. Company Revenue
- 8.7.3. Products
- 8.7.4. Recent Developments
8.8. UCB, Inc.
- 8.8.1. Company Overview
- 8.8.2. Company Revenue
- 8.8.3. Products
- 8.8.4. Recent Developments